Biofil Chemicals & Pharmaceuticals Limited
Biofil Chemicals and Pharmaceuticals Limited engages in manufacturing and trading of pharmaceuticals in India. It operates through Pharmaceutical and Chemical divisions. The company offers basic drugs and chemicals, such as sodium chloride, potassium chloride, sodium citrate, diethyl carbamazine citrate, ferrous sulphate, dried ferrous sulphate, ferrous fumerate, micro crystalline cellulose, and … Read more
Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) - Net Assets
Latest net assets as of September 2025: ₹213.04 Million INR
Based on the latest financial reports, Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) has net assets worth ₹213.04 Million INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹553.64 Million) and total liabilities (₹340.59 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹213.04 Million |
| % of Total Assets | 38.48% |
| Annual Growth Rate | 16.13% |
| 5-Year Change | 16.45% |
| 10-Year Change | 72.2% |
| Growth Volatility | 66.97 |
Biofil Chemicals & Pharmaceuticals Limited - Net Assets Trend (2008–2025)
This chart illustrates how Biofil Chemicals & Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biofil Chemicals & Pharmaceuticals Limited (2008–2025)
The table below shows the annual net assets of Biofil Chemicals & Pharmaceuticals Limited from 2008 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹187.82 Million | +3.18% |
| 2024-03-31 | ₹182.03 Million | +5.21% |
| 2023-03-31 | ₹173.01 Million | +2.76% |
| 2022-03-31 | ₹168.38 Million | +4.39% |
| 2021-03-31 | ₹161.29 Million | +8.37% |
| 2020-03-31 | ₹148.83 Million | +9.04% |
| 2019-03-31 | ₹136.50 Million | +3.66% |
| 2018-03-31 | ₹131.67 Million | +3.71% |
| 2017-03-31 | ₹126.96 Million | +16.41% |
| 2016-03-31 | ₹109.07 Million | +29.61% |
| 2015-03-31 | ₹84.15 Million | +7.02% |
| 2014-03-31 | ₹78.63 Million | +6.80% |
| 2013-03-31 | ₹73.62 Million | +7.70% |
| 2012-03-31 | ₹68.36 Million | +2.00% |
| 2011-03-31 | ₹67.02 Million | +287.97% |
| 2010-03-31 | ₹17.27 Million | +44.10% |
| 2009-03-31 | ₹11.99 Million | -18.90% |
| 2008-03-31 | ₹14.78 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biofil Chemicals & Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11365800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹162.74 Million | 86.65% |
| Other Comprehensive Income | ₹55.40 Million | 29.50% |
| Other Components | ₹83.33 Million | 44.37% |
| Total Equity | ₹187.82 Million | 100.00% |
Biofil Chemicals & Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Biofil Chemicals & Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AppSpotr AB
ST:APTR
|
$2.58 Million |
|
QUICKBIT EU AB O.N.
F:QBT
|
$2.58 Million |
|
Sentra Food Indonesia Tbk PT
JK:FOOD
|
$2.58 Million |
|
Public Company Management Corp
PINK:PCMC
|
$2.58 Million |
|
Mercator Limited
NSE:MERCATOR
|
$2.58 Million |
|
Bait Bakfar Ltd
TA:BKFR
|
$2.58 Million |
|
Interbud-Lublin SA
WAR:ITB
|
$2.58 Million |
|
OHB - Dusseldorf Stock Exchang
DU:OHB
|
$2.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biofil Chemicals & Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 182,028,000 to 187,816,000, a change of 5,788,000 (3.2%).
- Net income of 5,578,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 1.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹5.58 Million | +2.97% |
| Other Comprehensive Income | ₹-1.00 | -0.0% |
| Other Changes | ₹210.00K | +0.11% |
| Total Change | ₹- | 3.18% |
Book Value vs Market Value Analysis
This analysis compares Biofil Chemicals & Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.63x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 215.32x to 2.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-03-31 | ₹0.14 | ₹30.04 | x |
| 2009-03-31 | ₹0.20 | ₹30.04 | x |
| 2010-03-31 | ₹0.28 | ₹30.04 | x |
| 2011-03-31 | ₹4.12 | ₹30.04 | x |
| 2012-03-31 | ₹4.20 | ₹30.04 | x |
| 2013-03-31 | ₹4.52 | ₹30.04 | x |
| 2014-03-31 | ₹4.83 | ₹30.04 | x |
| 2015-03-31 | ₹5.17 | ₹30.04 | x |
| 2016-03-31 | ₹6.70 | ₹30.04 | x |
| 2017-03-31 | ₹7.80 | ₹30.04 | x |
| 2018-03-31 | ₹8.09 | ₹30.04 | x |
| 2019-03-31 | ₹8.39 | ₹30.04 | x |
| 2020-03-31 | ₹9.15 | ₹30.04 | x |
| 2021-03-31 | ₹9.91 | ₹30.04 | x |
| 2022-03-31 | ₹10.35 | ₹30.04 | x |
| 2023-03-31 | ₹10.63 | ₹30.04 | x |
| 2024-03-31 | ₹11.19 | ₹30.04 | x |
| 2025-03-31 | ₹11.41 | ₹30.04 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biofil Chemicals & Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.97%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.67%
- • Asset Turnover: 0.66x
- • Equity Multiplier: 2.71x
- Recent ROE (2.97%) is below the historical average (3.38%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -45.16% | -75.90% | 0.09x | 6.35x | ₹-8.15 Million |
| 2009 | -21.96% | -18.71% | 0.17x | 7.00x | ₹-3.83 Million |
| 2010 | 31.54% | 31.01% | 0.17x | 5.94x | ₹3.72 Million |
| 2011 | 14.80% | 46.09% | 0.21x | 1.55x | ₹3.22 Million |
| 2012 | 2.20% | 2.77% | 0.39x | 2.06x | ₹-5.33 Million |
| 2013 | 7.37% | 9.02% | 0.45x | 1.83x | ₹-1.94 Million |
| 2014 | 6.57% | 7.20% | 0.49x | 1.86x | ₹-2.70 Million |
| 2015 | 6.98% | 10.02% | 0.43x | 1.63x | ₹-2.54 Million |
| 2016 | 7.18% | 5.94% | 0.55x | 2.21x | ₹-3.08 Million |
| 2017 | 14.13% | 13.34% | 0.62x | 1.72x | ₹5.25 Million |
| 2018 | 3.57% | 3.81% | 0.51x | 1.83x | ₹-8.46 Million |
| 2019 | 3.53% | 2.09% | 0.96x | 1.77x | ₹-8.83 Million |
| 2020 | 8.11% | 4.07% | 0.70x | 2.85x | ₹-2.81 Million |
| 2021 | 7.70% | 3.47% | 1.08x | 2.06x | ₹-3.72 Million |
| 2022 | 4.15% | 3.12% | 1.19x | 1.11x | ₹-9.85 Million |
| 2023 | 3.24% | 1.87% | 0.96x | 1.82x | ₹-11.70 Million |
| 2024 | 3.90% | 1.77% | 0.85x | 2.59x | ₹-11.11 Million |
| 2025 | 2.97% | 1.67% | 0.66x | 2.71x | ₹-13.20 Million |
Industry Comparison
This section compares Biofil Chemicals & Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $12,445,167,922
- Average return on equity (ROE) among peers: 14.66%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biofil Chemicals & Pharmaceuticals Limited (BIOFILCHEM) | ₹213.04 Million | -45.16% | 1.60x | $2.58 Million |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.59 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |